Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients

Inclusion Criteria: * Males and females * 18 - 80 years (inclusive) of age * Clinically and genetically diagnosed as OPMD * Moderate dysphagia (abnormal drinking test at screening and on the first dosing day, before drug administration) * Patients who provide written informed consent to participate in the study * Body Mass Index (BMI) \<30 kg/m2 Exclusion Criteria: * Diabetes mellitus type 1 or 2 * Other major diseases, e.g.: renal failure (creatinine clearance \<60ml/min), liver failure and chronic liver diseases (e.g. hepatitis B or C) , HIV carriers, tuberculosis, SLE, rheumatoid polyarthritis, sarcoidosis, collagenosis * Uncontrolled heart disease , CHF, * Other neuromuscular diseases * Other disorders associated with esophageal dysphagia: e.g. severe gastroesophageal reflux (GERD), esophageal stricture due to mechanical or chemical trauma, infection (e.g. esophageal moniliasis), drug-induced dysphagia (e.g. bisphosphonates), esophageal rings and webs, spastic motility disorders of the esophagus. * History of malignancy (except non-invasive skin malignancy) * History of neck irradiation * Pregnant or currently lactating women * Obesity (BMI≥ 30) and associated morbidity * Prior pharyngeal myotomy * Weight loss of more than 10% in the last 12 months. * Known hypersensitivity to any ingredients in the injection * Patient receiving anticoagulant treatment (e.g. warfarin)